People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cybrexa Holding Company, LLC | — | Other | Series C | $42.4M | $625.1M | 2018 |
| CyVek, Inc. | — | Biotechnology | Series A | $22.3M | $361.5M | 2009 |
| CyOmics, Inc. | — | Biotechnology | Seed | $1.9M | $83.1M | 2016 |
| CyOmics, LLC | — | Biotechnology | Pre-Seed | $700K | $38.6M | 2015 |
Per Hellsund at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Per Hellsund on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| F. Kevin Didden | 4 | 6 |
| Kevin L. Rakin | 3 | 7 |
| Kevin Kevin Rakin | 2 | 2 |
| Kevin Rakin | 1 | 7 |
| John L. Houston | 1 | 1 |
| Enrique L. Posner | 1 | 1 |
| John Kevin Houston | 1 | 1 |
| David Kevin Wurzer | 1 | 1 |
| Enrique Kevin Posner | 1 | 1 |
| Michael L. Grillo | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.